Skip to main content

Branded Legacy, Inc. Expands Capabilities with Acquisition of State-of-the-Art GMP Facility in Vancouver

Written by Customer Service on . Posted in Mergers And Acquisitions.

Empowering BioLegacy to Lead Innovation in Combating the Opioid Epidemic Through Advanced Manufacturing and Research

VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) — via IBN — Branded Legacy, Inc. (OTC: BLEG), a pioneering biotechnology company dedicated to revolutionizing addiction treatment and harm reduction solutions, today announced that its subsidiary, BioLegacy Evaluative Group, has acquired a 22,000-square-foot commercial property in Vancouver, Canada. This strategic acquisition establishes a cutting-edge laboratory and manufacturing facility, fully compliant with Good Manufacturing Practices (GMP), positioning BioLegacy at the forefront of developing life-saving technologies to address the escalating opioid crisis.

Building on Branded Legacy’s recent transformative acquisition of BioLegacy Evaluative Group (formerly Menlo Health), which unlocked explosive growth potential in health innovation, as well as strategic partnerships with McMaster University for revolutionary clinical research in addiction treatment and with Stanford University’s Dr. Eran Bendavid to advance evidence-based addiction solutions, this new facility represents a critical milestone in the company’s overarching vision. By integrating world-class academic collaborations with in-house production capabilities, Branded Legacy is accelerating the creation of safe, effective devices and products that counteract hazardous substances and minimize associated harms, ultimately aiming to save lives and transform communities ravaged by addiction.

The acquired premises feature International Organization for Standardization (ISO) Class 7 and 8 clean rooms, essential for pharmaceutical and biotechnology product development. These controlled environments maintain stringent particle limits—ensuring no more than 352,000 particles per cubic meter =0.5 µm, 83,200 =1 µm, and 2,930 =5 µm in ISO 7 spaces—to guarantee the highest quality standards for sensitive manufacturing processes.

The in-house laboratory is equipped to handle a wide range of substances, including regular, potent, and controlled materials such as opioids, enabling BioLegacy to safely develop technologies tailored to high-risk applications. Complementing this, BioLegacy has active applications pending with Health Canada for Controlled Substances Licenses, underscoring the company’s commitment to regulatory compliance and ethical innovation.

Strategically located in Vancouver’s epicenter of the drug crisis, the facility fosters direct collaboration between BioLegacy Evaluative Group’s expert team and affected local populations. This proximity ensures that development efforts remain grounded in real-world challenges, enhancing the relevance and impact of solutions designed to mitigate the opioid epidemic’s devastating effects.

Dr. Kristian Thorlund, Executive Chair of BLEG, stated, “Dealing with the opioid epidemic means bringing devices and products to the populations using extremely hazardous materials. It is imperative that the products we develop can be used safely to both counter-act hazardous materials and work to minimize harms associated with them. These new facilities open up an enormous scientific capability for us.”

Amin Janmohomad, CEO of Branded Legacy, Inc., added, “This acquisition is a game-changer, aligning perfectly with our vision to build a comprehensive ecosystem for addiction solutions. By combining BioLegacy’s expertise with premier academic partnerships and now this advanced manufacturing hub, we’re not just responding to the crisis—we’re driving transformative change to significantly reduce its impact and support affected communities.”

About Branded Legacy, Inc.

Branded Legacy, Inc. (OTC:BLEG) is a holdings company focused on health and wellness, developing innovative solutions to combat addiction by preventing overdoses and supporting recovery. Its patented intranasal naloxone delivery device enhances accessibility and dosing precision for opioid overdose treatment. The platform also enables nasal delivery of vaccines and other medications, opening opportunities in global markets for rapid pandemic response and improved access in underserved regions, driving shareholder value.

Investor Relations: 
Branded Legacy, Inc.  
Email: info@brandedlegacy.com
Phone: 877-250-9077

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including projections regarding market growth, revenue potential, and development timelines, are based on current expectations and beliefs and involve risks and uncertainties that could cause actual results to differ materially. Branded Legacy undertakes no obligation to update these statements except as required by law.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.